Patent 10064801 was granted and assigned to OliX Pharmaceuticals on September, 2018 by the United States Patent and Trademark Office.
In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs and lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and for treating pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots.